Until the Expert Panel has further prospective data, especially when medical therapy resources are constrained, surgery of the primary tumor in appropriately selected patients with limited disease burden, bone-only disease, and ER-positive and/or HER2-positive disease, who can attain negative margin on surgery especially those younger than 55 years, is recommended. This evidence concerns the gene ERBB2 and glycogen storage disease VI.